Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.


Journal

Advances in cancer research
ISSN: 2162-5557
Titre abrégé: Adv Cancer Res
Pays: United States
ID NLM: 0370416

Informations de publication

Date de publication:
2024
Historique:
medline: 22 9 2024
pubmed: 22 9 2024
entrez: 21 9 2024
Statut: ppublish

Résumé

The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers concentrated doses of radiation via ionizing particles chelated to ligands or antibody-based molecules with specific tumor targets and is approved for patients with treatment resistant mCRPC. Variations of radionuclide therapies within the continuum of prostate cancer treatment are being investigated. Landmark phase III clinical trials of beta-emitting

Identifiants

pubmed: 39306369
pii: S0065-230X(24)00070-8
doi: 10.1016/bs.acr.2024.07.004
pii:
doi:

Substances chimiques

Radioisotopes 0
Radiopharmaceuticals 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

311-358

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Jeffrey Zhong (J)

Case Western Reserve University School of Medicine, Cleveland, OH, United States.

Albert Jang (A)

University Hospitals Seidman Cancer Center, Cleveland, OH, United States.

Jorge Garcia (J)

University Hospitals Seidman Cancer Center, Cleveland, OH, United States.

Norbert Avril (N)

University Hospitals Seidman Cancer Center, Cleveland, OH, United States.

Qiubai Li (Q)

University Hospitals Seidman Cancer Center, Cleveland, OH, United States.

Patrick Wojtylak (P)

University Hospitals Seidman Cancer Center, Cleveland, OH, United States.

Neal Shore (N)

Carolina Urologic Research Center, Myrtle Beach, SC, United States.

Scott Tagawa (S)

Weill Cornell Medical College of Cornell University, New York, NY, United States.

Pedro Barata (P)

University Hospitals Seidman Cancer Center, Cleveland, OH, United States. Electronic address: Pedro.barata@uhhospitals.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH